Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fosravuconazole - Seren Pharmaceuticals

Drug Profile

Fosravuconazole - Seren Pharmaceuticals

Alternative Names: BFE-1224; BMS-379224; E-1224; Fosravuconazole L-lysine ethanolate; NAILIN; Ravuconazole prodrug - Eisai

Latest Information Update: 28 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Drugs for Neglected Diseases Initiative Foundation; Eisai Co Ltd; Seren Pharmaceuticals
  • Class Antifungals; Antiprotozoals; Fluorobenzenes; Small molecules; Thiazoles; Triazoles
  • Mechanism of Action 14-alpha demethylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Registered Onychomycosis
  • Phase II Chagas disease; Dermatomycoses
  • Discontinued Mycoses

Most Recent Events

  • 28 Apr 2019 No recent reports of development identified for phase-I development in Chagas-disease(In volunteers) in Argentina (PO)
  • 11 Jul 2018 Sato Pharmaceutical and Eisai Co Ltd will launch fosravuconazole (NAILIN®) 100mg capsules for Onychomycosis in Japan on July 27, 2018
  • 19 Jan 2018 Registered for Onychomycosis in Japan - First global approval (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top